COVID-19 in solid organ transplant recipients: a single-center experience.
COVID-19
SARS-CoV-2
organ transplantation
solid organ transplantation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
05
2020
revised:
11
05
2020
accepted:
22
05
2020
pubmed:
28
5
2020
medline:
29
12
2020
entrez:
28
5
2020
Statut:
ppublish
Résumé
Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited, and the effective treatment strategy for these patients is unknown. We describe our institutional experience with COVID-19 in SOT. Demographic, clinical, and treatment data were extracted from the electronic patient files. A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n = 15 kidney; n = 1 kidney-after-heart; n = 3 lung, and n = 1 liver transplant recipient). The presenting symptoms were similar to nonimmunocompromised patients. Eighty-three percent (19/23) of the patients required hospitalization, but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty Scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only three patients were treated with chloroquine. Most patients recovered without experimental antiviral therapy. Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19.
Identifiants
pubmed: 32460390
doi: 10.1111/tri.13662
pmc: PMC7283727
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1099-1105Informations de copyright
© 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Virus Res. 2014 May 12;184:44-53
pubmed: 24566223
Am J Respir Crit Care Med. 2017 Jul 1;196(1):64-72
pubmed: 27922747
J Heart Lung Transplant. 2020 Jun;39(6):610-611
pubmed: 32340870
J Antimicrob Chemother. 2008 Mar;61(3):554-60
pubmed: 18230686
Am J Transplant. 2020 Jul;20(7):1879-1881
pubmed: 32243697
J Antimicrob Chemother. 2016 Dec;71(12):3340-3350
pubmed: 27585965
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Transplant. 2020 Jul;20(7):1891-1895
pubmed: 32243673
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
Am J Respir Cell Mol Biol. 2009 Nov;41(5):590-602
pubmed: 19244203
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Transpl Immunol. 2020 Aug;61:101304
pubmed: 32371150
Transplantation. 2020 Oct;104(10):1974-1983
pubmed: 32243281
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Antibiot (Tokyo). 2003 Aug;56(8):721-4
pubmed: 14563163
JAMA. 2020 Apr 21;323(15):1499-1500
pubmed: 32159735
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
ACS Cent Sci. 2020 Mar 25;6(3):315-331
pubmed: 32226821
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Hepatology. 2020 Oct;72(4):1491-1493
pubmed: 32220017
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
JAMA. 2020 May 12;323(18):1839-1841
pubmed: 32215647
Virus Res. 2012 Apr;165(1):112-7
pubmed: 22349148
Am J Transplant. 2020 Jul;20(7):1859-1863
pubmed: 32181990
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
J Heart Lung Transplant. 2020 May;39(5):496-497
pubmed: 32362394